We have investigated the regulatory role of DNA methylation in the expression of the human histo-blood group ABO genes. The ABO gene promoter region contains a CpG island whose methylation status correlates well with gene expression in the cell lines tested. The CpG island was found hypomethylated in some cell lines that expressed ABO genes, whereas the other cell lines that did not express ABO genes were hypermethylated. The ABO blood group system discovered by Karl Landsteiner (1) at the beginning of this century is of great importance in blood transfusions and organ transplantations. Two carbohydrate antigens, A-and B-antigens, and their antibodies constitute this system. The A and B functional alleles at the ABO genetic locus encode glycosyltransferases ␣133GalNAc transferase (designated A-transferase) and ␣133Gal transferase (designated B-transferase), respectively. A-transferase transfers a GalNAc residue from UDP-GalNAc to the precursor H substrate, producing A antigens as defined by the trisaccharide determinant structure, GalNAc␣133(Fuc␣132)Gal␤13 R. Similarly, B-transferase catalyzes the transfer of a Gal from UDP-Gal to the same H substrate, producing B antigens defined by Gal␣133(Fuc␣132)Gal␤13 R (2-5). Molecular genetic studies of the human ABO genes have identified two critical single base substitutions that result in amino acid substitutions responsible for the different donor nucleotidesugar substrate specificity between A-and B-transferases. A single base deletion, which shifts the reading frame of codons and abolishes the function of A-transferase, has been identified in most O alleles (6, 7).
The ABO blood group system discovered by Karl Landsteiner (1) at the beginning of this century is of great importance in blood transfusions and organ transplantations. Two carbohydrate antigens, A-and B-antigens, and their antibodies constitute this system. The A and B functional alleles at the ABO genetic locus encode glycosyltransferases ␣133GalNAc transferase (designated A-transferase) and ␣133Gal transferase (designated B-transferase), respectively. A-transferase transfers a GalNAc residue from UDP-GalNAc to the precursor H substrate, producing A antigens as defined by the trisaccharide determinant structure, GalNAc␣133(Fuc␣132)Gal␤13 R. Similarly, B-transferase catalyzes the transfer of a Gal from UDP-Gal to the same H substrate, producing B antigens defined by Gal␣133(Fuc␣132)Gal␤13 R (2-5). Molecular genetic studies of the human ABO genes have identified two critical single base substitutions that result in amino acid substitutions responsible for the different donor nucleotidesugar substrate specificity between A-and B-transferases. A single base deletion, which shifts the reading frame of codons and abolishes the function of A-transferase, has been identified in most O alleles (6, 7) .
The ABO genes are expressed in a cell type-specific manner; the isoantigens A, B, and H of blood groups A, B, and O are not confined to red cells only but are also found in most secretions and on some epithelial cells. However, they are absent in connective tissues and the central nervous system (8) . ABH antigens are known to undergo drastic changes during development, differentiation, and maturation of normal cells (9) . In addition to these physiological processes, profound changes have also been documented in pathological processes such as tumorigenesis. Reduction or complete deletion of A/B antigen expression in bladder and oral cancers has been documented, as well as the apparent onco-developmental expression of the ABH antigens in gastric and distal colon tumors (10 -12) . Moreover, the loss of ABH antigens has been correlated with tumor progression of various carcinomas including lung and bladder carcinomas (13) (14) (15) (16) . Thus, delineation of regulatory mechanism is essential to understand these complicated expression patterns of the ABO genes.
In an initial attempt to elucidate the molecular mechanism controlling the expression of the human ABO genes, we isolated several genomic clones that covered the ABO genes over 18 kb 1 (17) . A 4.7-kb EcoRI/NcoI 5Ј-upstream fragment flanking the coding sequence in exon 1 of the human ABO gene was subcloned into the promoterless pGL3-basic vector upstream of the luciferase coding sequence, and a series of nested deletion constructs were prepared. Transient transfection assays were performed to analyze the promoter activity of the respective constructs using gastric cancer cell line KATOIII as the recipient of DNA. Results demonstrated that the sequence just upstream of the transcription start site was responsible for the transcriptional activity of the ABO genes (18) . Inspection of the promoter region revealed the presence of several GC boxes just upstream of the transcription initiation sites. However, no sequence motifs were found for tissue-specific DNA-binding proteins. Thus, there should be additional controlling mechanism(s) to account for the expression patterns of the human ABO genes.
Methylation of cytosine residues in the dinucleotide CpG may offer one such mechanism because it is well known to control cell type-specific transcriptional regulation in various other genes, including myo-D gene (19) . CpG island hypermethylation has often been found to be associated with transcriptional inactivation of specific tumor suppressor genes in neoplastic cells (20) . Therefore, we have investigated the possible role of DNA methylation in the ABO gene expression.
MATERIALS AND METHODS
Cell Culture-Human gastric cancer cell lines MKN28 (JCRB0253) and MKN45 (JCRB0254), erythroleukemic cell lines K562 (JCRB0019) and HEL (JCRB0062), and T cell line Jurkat (RCB0806) were grown in RPMI 1640 supplemented with 10% fetal bovine serum (FBS) (Life Technologies, Inc.) and 0.5% penicillin/streptomycin. A human gastric cancer cell line KATOIII (JCRB0611) was grown in 45% RPMI 1640 plus 45% minimum essential medium (MEM) containing 10% FBS and 0.5% penicillin/streptomycin. A human glioblastoma cell line T98G (JCRB9041) was grown in MEM supplemented with 10% FBS, 0.5% penicillin/streptomycin, 100 M nonessential amino acids, and 1 mM sodium pyruvate (Life Technologies, Inc.).
Reverse Transcription-PCR (RT-PCR)-Total RNA was isolated from cultured cells using the acid guanidine thiocyanate/acid phenol method (21) . cDNA was synthesized from total RNA (2 g) using random hexamers and Superscript II (Life Technologies, inc.). One l out of 20 l of the resulting single strand cDNA reaction was used as a template for RT-PCR. Five l of Marathon-Ready cDNA of human bone marrow (CLONTECH) was also used as a template for PCR. The sequences of the primers used to amplify the ABO gene messages were 5Ј-CCAGA-AGTCTAATGCCAGGAAGCCTGGAAC-3Ј (sense primer, ABOϩ116) and 5Ј-CCCCCAGGTAGTAGAAATCGCCCTCGTCCTT-3Ј (antisense primer, ABOϩ802), and they corresponded to the sequences located in exons 3 and 7 of the gene, respectively. Primer ABOϩ802 is identical to the ABO80 primer reported by Ørntoft et al. (22) . Conditions for ABO amplification were 95°C for 9 min, 40 cycles of 94°C for 1 min, 63°C for 1 min, and 72°C for 2 min, followed by incubation at 72°C for 10 min. RT-PCR was also performed using primers for glyceraldehyde-3-phosphate dehydrogenase (G3PDH) gene messages as a control. Primers for the G3PDH gene were 5Ј-TCCACCACCCTGTTGCTGTAG-3Ј (sense) and 5Ј-GACCACAGTCCATGACATCACT-3Ј (antisense). Conditions for G3PDH amplification were 95°C for 9 min, 35 cycles of 94°C for 1 min, 55°C for 1 min, and 72°C for 2 min, followed by incubation at 72°C for 10 min. Both PCR amplifications were performed in a 100-l reaction mixture containing 20 pmol of each primer, 2.5 units of AmpliTaq Gold (Perkin-Elmer), 1.5 mM MgCl 2 , 150 M dNTP, and 1ϫ buffer (PerkinElmer). The products were resolved on a 2% agarose gel. The identity of the ABO cDNA was confirmed by sequencing and Southern blot hybridization. After cloning of the PCR-amplified products into a pCR2.1 plasmid vector (Invitrogen, San Diego, CA), sequence was determined using the ABI PRISM dRhodamine Terminator Cycle Sequencing Ready Reaction Kit with AmpliTaq DNA Polymerase FS (PerkinElmer) with both M13 forward and reverse primers. For Southern blot analysis, the PCR-amplified products resolved on a 2% agarose gel were transferred onto a nylon membrane (Hybond-Nϩ; Amersham Pharmacia Biotech). The probe was prepared by a PCR amplification method using the EcoRI-digestive fragment from a plasmid pAAAA (7) as a template. In order to label the probe, [ 32 P]dATP was used in place of nonradioactive dATP in the PCR reaction. The primers used for amplification were ABOϩ802 and ABOϩ415, 5Ј-CGGAATTCAAGCACT-TCATGGTGGGCCA-3Ј. The amplification was performed under the following conditions: 95°C for 9 min, 30 cycles of 94°C for 30 s, 55°C for 30 s, and 72°C for 45 s, followed by incubation at 72°C for 10 min. The reaction was carried out in a 100-l reaction mixture containing 100 pmol of each primer, 5 units of AmpliTaq Gold, 1.5 mM MgCl 2 , 150 M dNTP, and 1ϫ buffer. The ABO blot was prehybridized in 5ϫ SSPE, 5ϫ Denhardt's solution, 20 g/ml salmon sperm DNA, and 0.5% SDS solution at 65°C for 1 h and then hybridized overnight at 65°C with the 32 P-labeled A-transferase cDNA sequence probe. The membrane was washed twice in 2ϫ SSPE and 0.1% SDS at room temperature for 10 min, three times in 1ϫ SSPE and 0.1% SDS at 65°C for 2 h, and then once in 0.1ϫ SSPE and 0.1% SDS at 65°C for 1 h, followed by autoradiography.
Bisulfite Modification and Genomic Sequencing-Bisulfite genomic sequencing was performed as described by Clark et al. (23) under conditions that allowed the conversion of cytosine, but not 5-methylcytosine, to uracil. Briefly, DNA (200 -400 ng) in a volume of 20 l was denatured by NaOH (final concentration, 0.3 M) for 15 min at 75°C. Freshly prepared 14 l of 10 mM hydroquinone (Sigma) and 250 l of 4.8 M sodium metabisulfite (Sigma) at pH 5.0 were added and mixed. The samples were then incubated under mineral oil at 55°C for 16 -20 h. Modified DNA was purified using the Glassmax DNA isolation spin cartridge system according to the manufacturer's protocol (Life Technologies, Inc.). Modification was completed by NaOH (final concentration, 0.3 M) treatment for 5 min at room temperature, followed by ethanol precipitation. DNA was resuspended in water and used immediately or stored at Ϫ20°C.
Because methylation of cytosine residue in CpG dinucleotide appears symmetrical on either strand of DNA, the upper strand of the bisulfitemodified ABO promoter was amplified with ABO gene-specific primers for the modified sequence, 5Ј-GGGGATAGGGTTTTAAGGTATTA-3Ј (sense primer, F) and 5Ј-CAACACCTC(A/G)ACCATAACTCC-3Ј (antisense primer, R). PCR conditions used were the following: 95°C for 9 min, 40 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 2 min, and finally 10 min at 72°C. PCR amplification was performed in a 100-l reaction mixture containing 100 pmol of each primer, 2.5 units of AmpliTaq Gold, 1.5 mM MgCl 2 , 150 M dNTP, and 1ϫ buffer. Amplified DNA was electrophoresed, gel-purified, and ligated with pCR2.1. Sequencing was then performed with double-stranded plasmid templates, and 8 -20 clones were sequenced per cell line.
Methylation-specific PCR (MSP)-DNA methylation patterns in the CpG islands of the ABO genes were determined by chemical treatment with sodium bisulfite and subsequent PCR. Primer sequences for the unmethylated reaction were 5Ј-GGATAGGGTTTTAAGGTATTAGGG-TTATG-3Ј (sense primer, U1) and 5Ј-CCACATCTAATCTCAAC-CTCCA-3Ј (antisense primer, U2). PCR conditions for the unmethylated reaction were the following: 95°C for 9 min, 38 cycles of 94°C for 1 min, 60°C for 1 min, 72°C for 2 min, and finally 10 min at 72°C. Primer sequences for the methylated reaction were 5Ј-TTAAGGTATTAGGGT-TACGAGGGGC-3Ј (sense primer; M1) and 5Ј-CGACCATAACTC-CGCGTCT-3Ј (antisense primer; M2). PCR conditions for the methylated reaction were the following: 95°C for 9 min, then 38 cycles of 94°C for 1 min, 67°C for 1 min, 72°C for 2 min, and finally 10 min at 72°C. PCR amplification was performed in a 50-l reaction mixture containing 50 pmol of each primer, 2.5 units of AmpliTaq Gold, 1.5 mM MgCl 2 , 150 M dNTP, 1ϫ buffer, and bisulfite-modified DNA (Ϸ20 ng) or unmodified DNA (20 -40 ng) . The products were resolved on a 2% agarose gel. Nucleotide sequences of the PCR-amplified products with the unmethylated primers and methylated primers were determined as described above.
DNA Transfection-Luciferase reporter vector plasmid SN contains the ABO gene sequence between Ϫ117 and ϩ31 and plasmid NaN contains the Ϫ35 to ϩ31 sequence, as described previously (18) . KA-TOIII cells were transfected with 6 g of plasmid DNA by electroporation as described (18) . Jurkat cells were also transfected with plasmid DNA by electroporation. The cells were split to 3 ϫ 10 5 /ml 16 -24 h prior to transfection. At the time of transfection, cells were harvested by centrifugation at 500 ϫ g for 10 min. Cells were washed twice with RPMI 1640 containing neither FBS nor L-glutamine. The cells were resuspended at 1 ϫ 10 7 cells/ml. 0.8 ml of cell suspension was placed into a 0.4-cm electroporation cuvette (Bio-Rad). Six micrograms of supercoiled plasmid DNA was added to the cell suspension in the cuvette. Cells were incubated with plasmid DNA for 5 min at room temperature prior to electroporation at 960 microfarads and 280 V. Immediately after transfection, the cuvettes were transferred to an ice bath and kept for 15 min. The cells were then transferred into 10 ml of growth medium and incubated for 24 h before being harvested for luciferase and ␤-galactosidase assays. MKN28 cells and T98G cells were transfected with Lipofectin (Life Technologies, Inc.). The cells were split to 1 ϫ 10 5 /ml in a six-well tissue culture plate (Becton Dickinson Labware, Franklin Lakes, NJ) 18 -24 h prior to transfection. At the time of transfection, cells were washed once with MEM containing neither FBS nor Lglutamine. Two micrograms of supercoiled plasmid DNA was suspended in 100 l of Opti-MEM I reduced serum medium (Life Technologies, Inc.). Five l of Lipofectin reagent was diluted in 100 l of Opti-MEM I reduced serum medium. The two solutions were combined at room temperature for 10 -15 min, followed by addition of 0.8 ml of Opti-MEM I reduced serum medium. The mixture was then overlaid onto the cells. MKN28 cells and T98G cells were incubated for 12 and 8 h, respectively, before the DNA-containing medium was replaced with 2 ml of growth medium containing serum. MKN28 cells and T98G cells were harvested for luciferase and ␤-galactosidase assays at 36 and 48 h, after replacement of the medium. HEL cells were transfected with DMRIE-C reagent (Life Technologies, Inc.). The cells were split to 3 ϫ 10 5 /ml 16 -24 h prior to transfection. At the time of transfection, cells were harvested by centrifugation at 500 ϫ g for 10 min at room temperature. Cells were washed twice with RPMI 1640 containing neither FBS nor L-glutamine at room temperature. Five l of DMRIE-C reagent was mixed with 0.5 ml of Opti-MEM I reduced serum medium in each well of a six-well plate. 0.5 ml of Opti-MEM I reduced serum medium containing 6 g of plasmid DNA was added to each well, followed by incubation for 45 min. 2 ϫ 10 6 cells in 0.2 ml of Opti-MEM I reduced serum medium was added to each well and incubated for 5 h before adding 2 ml of RPMI 1640 containing 15% FBS. HEL cells were harvested for luciferase and ␤-galactosidase assays at 24 h after addition of growth medium.
Luciferase Assay-Cell lysis and luciferase assays were performed using the Luciferase Assay System (Promega, Madison, WI). Light emission was measured in a model Luminous CT-9000D luminometer (Dia-Iatron, Tokyo, Japan), and values were obtained in relative light units. For all transient expression assays, the light emission observed fell within the linear range of previously determined titration curves (light emission observed versus amount of luciferase protein). Variations in transfection efficiency were normalized to the activities of ␤-galactosidase expressed from 2 or 0.6 g of cotransfected plasmid containing the Rous sarcoma virus (RSV) long terminal repeat directing Escherichia coli ␤-galactosidase expression. ␤-Galactosidase activities were measured as described elsewhere (24) . Two g of plasmid DNA was cotransfected into KATOIII cells, Jurkat cells, and HEL cells, whereas 0.6 g of the plasmid was cotransfected into MKN28 cells and T98G cells. Activity of the pGL3-promoter vector containing the SV40 promoter was used to assign an arbitrary value of 1.0 to facilitate the comparison of the values obtained from different experiments.
In Vitro DNA Methylation-Recombinant HhaI methylase was used to methylate pGL3-basic vector and the ABO promoter/luciferase reporter constructs. Plasmid DNA was incubated with 5 units of the HhaI methylase per g of DNA in 50 mM Tris-HCl (pH 7.5), 10 mM EDTA, 80 M S-adenosylmethionine, and 5 mM 2-mercaptoethanol. Reactions were carried out at 37°C overnight. Complete methylation was confirmed by the resulting resistance against HhaI restriction endonuclease digestion analyzed by agarose gel electrophoresis. Only samples that were protected from HhaI restriction enzyme digestion were used in the transfection experiments.
In Vivo Demethylation of MKN28 Cells-MKN28 cells were seeded at 1.5 ϫ 10 5 /ml in 25 ml of normal growth medium, and 2.5, 12.5, or 25 l of 10 mM 5-aza-2Ј-deoxycytidine purchased from Sigma was added (1, 5, or 10 M final concentration, respectively). Cells were incubated for 5 days before harvesting total RNA and DNA. For immunostaining, MKN28 cells were seeded at 3 ϫ 10 4 /ml and cultured with growth medium containing 5-aza-2Ј-deoxycytidine at 5 and 10 M for 5 days before fixation for immunostaining.
Immunostaining of Cell Surface Blood Group A-Antigens-According to the method of Pattnalk et al. (25, 26) , surface A-antigens of MKN28 and MKN45 cells were immunologically examined using immunofluorescence. MKN45 cells were used as positive control because we observed large amounts of A-antigens on their cell surfaces (26) . Since treatment of erythrocytes with proteolytic enzymes is known to have no effect on the ABH antigens, the cells were dispersed with trypsin. The cells were promptly dried on glass slides and were fixed in 0.072 M cacodylate buffer (pH 7.5) containing 1% para-formaldehyde and 0.72% sucrose for 30 min at 4°C. The fixed cells were incubated with murine anti-A monoclonal antibody mixture (Ortho Diagnostics, Raritan, NJ) in a humidified chamber at 37°C for 3 h. The cells were then washed with phosphate-buffered saline and incubated with fluorescein-conjugated goat anti-mouse IgM antibody (Tago, Burlingame, CA) at 37°C for 1 h. The frequencies of A-positive cells were obtained from three independent experiments.
RESULTS
Defining the 5Ј CpG Island in the ABO Genes-Previous characterization of the 5Ј upstream sequence of the ABO genes indicates that the region between Ϫ117 and ϩ31 has promoter activity and is sufficient to direct the expression of a reporter gene when placed 5Ј adjacent to the reporter gene (18) . Inspection of the promoter region reveals the presence of several GC boxes just upstream from the transcription initiation sites, whereas known sequence motifs for tissue-specific DNA binding proteins are not present. Partial sequence between Ϫ246 and ϩ50 of the human ABO genes is shown in Fig. 1 . The nucleotide sequence around the 5Ј upstream region of the ABO genes reveals that the GC-rich region extends from the immediate 5Ј-flanking region through the first exon and into the first intron as shown in Fig. 2 . This nucleotide sequence has been deposited to GenBank TM by us and by others (GenBank TM accession numbers U22302, AF014105, and AC000397). This region fulfills the criteria for a CpG island by having a G ϩ C content of 76% and a CpG/GpC ratio of 0.9 (27) . Two Alu repeats are present 5Ј to the CpG island in inverse orientations. The proximal Alu repeat is located immediately 5Ј to the CpG island and within 1 kb upstream of the transcription start sites. Recently, a number of CpG islands have been found juxtaposed to multiple Alu repeats as reported by Graff et al. (28) . Approximately half of the genes, or some 40,000 -50,000 genes in mice and humans have a 5Ј CpG island (29) . These are largely the "housekeeping" genes, which have a broad tissue expression pattern. However, there are also many tissue-specific genes that contain 5Ј CpG islands (27, 29, 30 (17) . The motifs for transcription factor Sp1 are indicated (underbars).
tissue-specific expression of various genes (19, (31) (32) (33) . Furthermore, a 5Ј CpG island hypermethylation is well known to be associated with transcriptional inactivation of certain cancerrelated genes in neoplastic cells (20) . Therefore, we next investigated the possibility that DNA methylation of the ABO genes controls gene expression in tissue-specific manner, as well as silencing in tumors.
Inverse Correlation of the Hypermethylation of the ABO Gene Promoter with the Gene Expression Level-Since inverse correlation between transcriptional activation and hypermethylation of local CpG sites has been reported for a number of genes in association with cell type-specific expression and repression during tumorigenesis, we first examined the expression status of the ABO genes at the RNA and the protein (enzyme) levels in various cell lines. Since DNA methylation has been observed to determine the tissue-specific expression of a gene (19, (31) (32) (33) , the cell lines derived from tissues originally expressing and not expressing the ABH antigens were investigated to address whether DNA methylation of the ABO promoter region is involved in regulation of tissue-specific expression of the ABO genes. The origins, the genotypes, and the enzyme levels of these cell lines are shown in Table I . Although gastric mucosa and erythroid cells are well known to express the ABH antigens, these antigens are undetectable in T-lymphocytes and glial cells (8, 34) . We employed RT-PCR because it showed higher resolution of the ABO transcripts compared with the resolution of Northern blot analysis (data not shown). Moreover, RT-PCR are informative on the splicing patterns of the ABO transcripts. We used two primers corresponding to the sequences in exons 3 and 7. Results from RT-PCR analysis demonstrated the presence of ABO transcripts in human gastric cancer cell lines MKN45 and KATOIII, as well as human erythroleukemia cell lines K562 and HEL (Fig. 3A) . In sharp contrast, the ABO transcript was barely detected in MKN28 cells, Jurkat cells, and T98G cells, whereas the intensities of the control G3PDH transcripts were similar to those observed in the other cells expressing ABO transcripts. As shown in Table I , A-transferase activity was not detectable in Jurkat cells whose ABO genotype was determined to be AO by PCR restriction fragment length polymorphism (PCR-RFLP) (35) . The expression status of the ABO genes in Jurkat and T98G cells appeared to reflect the characteristics of cell types where these cell lines were derived, T-lymphocytes and glial cells, respectively. Human gastric cancer cell line MKN28 was de- (26) . The activity of B-transferase of KATOIII cells was reported previously (18) .
e -, not tested.
FIG. 2. Defining the 5 CpG island in the ABO gene.
The top diagram indicates ABO gene exon 1 and its flanking region. The sequence located between Ϫ2000 and ϩ2000 relative to the upstream transcription start site of the ABO genes was compiled from GenBank TM accession number AC00397. The schematic shows the location of the first exon in the ABO gene as a closed box, whereas the small closed arrow represents the upstream transcription start site. The second exon is not indicated in the figure, since it is located 13 kb downstream from the first exon. The open arrows represent the position and orientation of the Alu sequences, which were assigned by homology search of sequence U14574 with the Alu repeat data base of the National Center for Biotechnology using BLAST algorithm. The 5Ј Alu sequence shows 82% homology with the 3Ј Alu sequence, although these Alu sequences are located in the opposite direction. The middle mountain plot shows the G ϩ C density in the sequence between Ϫ2.0 and ϩ2.0 kb. The plot was constructed using GENETYX-SV/RC10.1 with an average span of 100 and a step of 1. The plot shows that the sequence between Ϫ0.7 kb to ϩ0.6 kb includes a G ϩ C content of greater than 60%. The bottom portion of the figure represents the distribution of CpG dinucleotides in the ABO gene 5Ј region. The vertical lines indicate the position of each CpG dinucleotide in the DNA sequence from positions Ϫ2000 to ϩ2000 relative to the upstream transcription start site of the ABO gene. Dense clustering of CpG sites is shown in the sequence between Ϫ0.7 kb and ϩ0.6 kb in which CpG density is 11.7%.
rived from a tumor of a blood group A individual, 2 this being consistent with the result of PCR-RFLP that an A allele was present in genomic DNA ( Table I) . As expected from RT-PCR results, A-transferase activity was undetectable in cell extract prepared from MKN28 cells. Moreover, A-antigens were not observed by immunofluorostaining of MKN28 cells with anti-A antibody (data not shown), whereas H antigens, precursors of A-antigens, were detected using a neutralization test of chicken anti-H antiserum with the cell extract prepared from the MKN28 cells (data not shown). Taken together, the loss of antigen expression may be due to the down-regulation of transferase mRNA transcription in the nonexpressor cells. Ørntoft et al. (22) previously came to the similar conclusion based on their studies on bladder tumors.
The results of RT-PCR analysis also showed different banding patterns among the cell lines that expressed the ABO gene messages. Whereas the RT-PCR products of different sizes were shown in human erythroleukemia cell lines K562 and HEL, the products of human bone marrow cDNA were a major full-length transcript A and a minor transcript D (data not shown). Nucleotide sequences were determined using dRho- ucts are schematically represented in Fig. 3B . Alternative splicing transcripts B to F are in frame. Stop codons occur in transcripts D and F at the splicing junctions. Removal of exons 5-6 in transcript E would theoretically nullify the frameshifting effect caused by a single nucleotide deletion identified in most O alleles and thus lead to the appearance of an "incompatible A antigen" in certain tumors of blood group B and O individuals (36) . However, A-transferase activity was not detected in K562 cells and HEL cells whose genotypes were determined to be OO by PCR-RFLP (Table I ). This suggests that the sequence in exon 6 may be necessary to encode the functional enzymes. Conservation of the sequence in exon 6 among four glycosyltransferases (A/B transferases, UDP-galactose:Gal␤1, 4GlcNAc ␣133 galactosyltransferase, and Forssman synthetase) may also support this hypothesis (37) . Mechanisms other than alternative splicing may be responsible for this interesting phenomenon.
We next examined the methylation status of the ABO promoter region in the cell lines used in the RT-PCR experiments. The cytosine methylation of the CpG dinucleotides in the Ϫ200 to ϩ26 sequence of the ABO genes, which is defined by primers F and R (see Fig. 1 ), was analyzed by the sodium bisulfite modification method (23) . After bisulfite treatment, a discrete PCR product of 280 bp was obtained. Sequencing of each cloned PCR product was performed to demonstrate the methylated/ unmethylated status of the respective CpG sites within the region. Amounts of methylated CpG sites in the Ϫ117/ϩ26 ABO promoter sequence are shown in Fig. 4A . All the cytosine residues except for those at CpG nucleotides in the original sequence were converted to thymidines, suggesting the completeness of the bisulfite conversion. Some of the cytosine residues of CpG were methylated in all the clones obtained from the ABO gene promoter region from MKN28 cells, Jurkat cells, and T98G cells in which the ABO transcript was barely detectable by RT-PCR. In contrast, none of cytosine residues were methylated in CpG dinucleotides between positions Ϫ200 and ϩ26 in MKN45, KATOIII, and K562 cells, which were demonstrated to express the ABO genes. In HEL cells expressing the ABO genes, all cytosine residues in CpG were converted in some PCR products but not in others, indicating the possibility of cellular heterogeneity in DNA methylation within a culture. Therefore, DNA methylation of the ABO gene promoter was inversely correlated with the transcription of the ABO genes. These findings implicate that alterations in DNA methylation may be one of the mechanisms regulating the ABO genes expression.
Not all the cytosine residues in CpG dinucleotides were methylated in the Ϫ117 to ϩ26 sequence in those nonexpressing cells. This differs with the observation that all CpGs were methylated in the 235-bp -globin gene promoter in genomic DNA from adult chicken erythroid cells (32) . However, a high heterogeneity of the methylation patterns within the nonexpressor cells was reported in the genes encoding galectin-1, prolactin, and growth hormone (38 -39) . To address the issue of heterogeneous methylation patterns, the percentages of methylated cytosine residues in individual CpG sites were calculated in the Ϫ200 to ϩ26 sequence in MKN28 cells, Jurkat cells, and T98G cells (Fig. 4B) . The CpG sites between region Ϫ1 and ϩ26 appeared to be preferentially methylated in either MKN28 cells or T98G cells, whereas the CpG sites between region Ϫ120 and Ϫ114 were methylated at low frequencies. In Jurkat cells, the CpG sites between region Ϫ1 and ϩ26 were highly methylated, although the methylation ratios were higher between the Ϫ200 to ϩ26 sequence. Therefore, there seems to be a heterogeneity of methylation profile not only in quantitative manners but also in locations.
For rapid analysis of the methylation status of the CpG island in the ABO genes, we designed primers for methylationspecific PCR (MSP), such that the heterogeneity of methylation frequency at each CpG site in the Ϫ200 to ϩ26 sequence of the ABO genes was considered. We tested the primers designed for the ABO gene promoter sequence on DNA from cancer cell lines for which the methylation status was demonstrated by bisulfite genomic sequencing. Control reactions with untreated DNA demonstrated that PCR reactions were obtained only with bisulfite-treated DNA for unmethylated and methylated primer sets (data not shown). In all cases, the primer set used confirmed the methylation status determined by bisulfite genomic sequencing. For example, DNA from expressor cell lines MKN45, KATOIII, and K562 with unmethylated ABO alleles amplified only with the unmethylated primers (Fig. 4C) . DNA from nonexpressor cell lines MKN28, Jurkat, and T98G, having only methylated ABO alleles, amplified only with methylated primers. After bisulfite treatment, DNA from the cell line HEL produced a similar amplification with either unmethylated primers or methylated primers, which was consistent with the result of bisulfite genomic sequencing. Nucleotide sequencing of these bands confirmed that PCR-amplified products with the unmethylated primers were derived from hypomethylated alleles, whereas those with the methylated primers were from hypermethylated alleles. Therefore, MSP appears to be available for analyzing rapidly the methylation status of the CpG island in the ABO genes.
Inhibition of the ABO Promoter Activity by ex Vivo DNA Methylation-By performing transient transfection experiments in gastric cancer cells, the ABO cap site-proximal region located between Ϫ117 to ϩ31 was found to be responsible for transcriptional activity (18) . In order to examine whether the ABO gene promoter exhibited cell type-specific activity correlating with endogenous expression of the ABO genes, transient transfection studies were performed using the nonexpressing cells. Since the simian virus 40 (SV40) promoter showed activity independent of cell types, the relative promoter activities of SN construct to the activity of pGL3-promoter vector containing the SV40 promoter were calculated and compared with one another (Table II) . In all the cell lines tested, the promoter construct SN was 10-to ϳ20-fold more active than the control pGL3-basic vector, indicating that the extraneously introduced ABO gene promoter was constitutively active in the nonex- a The results are expressed as an average relative activity compared with that observed for the pGL3-promoter vector containing the SV40 promoter. Standard deviations are indicated for a minimum of three repetitions.
b Either KATOIII cells or Jurkat cells were transfected with electroporation; 4 g of luciferase reporter and 2 g of ␤-galactosidase control vector were used for each analysis.
c Either MKN28 cells or T98G cells were transfected with Lipofectin reagent; 1.4 g of luciferase reporter and 0.6 g of ␤-galactosidase control vector were used for each analysis.
d HEL cells were transfected with DMRIE-C reagent; 4 g of luciferase reporter and 2 g of ␤-galactosidase control vector were used for each analysis.
e The ABO promoter used sequences located between Ϫ117 to ϩ31.
pressing cells. These observations also support the hypothesis that DNA methylation, a generalized negative regulatory mechanism, may play a role in regulation of the ABO gene transcription by repressing the constitutive active promoter. The effect of ex vivo methylation on the promoter activity of the human ABO genes was investigated through transient transfection experiments. HhaI methylase was chosen for a definite evaluation of ex vivo DNA methylation. HhaI site is absent from the Ϫ35 to ϩ31 ABO promoter sequence in the construct NaN, whereas three HhaI sites are present in the Ϫ117 to ϩ31 sequence in SN as shown in Fig. 1 . Effects of the HhaI methylation of the Ϫ117 to Ϫ35 sequence on the transcriptional activity is represented by comparing the difference of reporter activities between HhaI-methylated SN and NaN to the difference between control SN and NaN. First, the ABO promoter/luciferase reporter constructs were methylated in vitro by HhaI methylase, a site-specific DNA methylase. To determine whether all the HhaI sites were methylated, the methylated plasmid DNA was digested with methylation-sensitive HhaI. The control plasmid DNA was cut with HhaI, whereas the methylated plasmid DNA was not (Fig. 5A) . Subsequently, both the methylated and the control plasmid DNA was transfected into KATOIII cells, a gastric cancer cell line that showed a high level of promoter activity after transfection with the ABO promoter constructs. The promoter activity of methylated NaN construct was similar to that observed in the   FIG. 5 . Effect of methylation on the activity of the ABO promoter-reporter gene constructs. A, methylation of plasmid DNA was determined using a methylation-sensitive restriction enzyme. The vectors pGL3-basic vector, NaN, and SN were methylated by site-specific methylase HhaI in vitro. Subsequently, the methylated plasmid DNA and the control plasmid DNA were digested by methylation-sensitive restriction enzyme HhaI and fractionated on a 1% agarose gel. B, transient transfection of KATOIII cells with methylated reporter constructs. KATOIII cells were cotransfected with 2 g of RSV long terminal repeat/␤-galactosidase and 4 g of methylated or control vectors SN, NaN, pGL3-basic vector or pGL3-promoter vector for 48 h, followed by a luciferase assay and a ␤-galactosidase assay. Relative luciferase activities of the respective constructs (normalized to RSV long terminal repeat/␤-galactosidase expression, to control for transfection efficiency) are represented at the right as the mean from more than three independent experiments. Results are expressed as a relatively average activity. Activity of the unmethylated pGL3-promoter vector containing the SV40 promoter is assigned an arbitrary value of 1.0, and the standard deviations are indicated for a minimum of three repetitions. Putative methylated CpG sites recognized by HhaI methylase are depicted by closed bubbles, and the unmethylated CpG sites are depicted by open bubbles.
control NaN (Fig. 5B) . However, in vitro methylation of the construct SN resulted in a loss of two-thirds of luciferase activity compared with the activity of control SN. This suggests that inhibition was partly due to methylation of the three HhaI CpG sites in the Ϫ117/ϩ31 ABO promoter sequence. Therefore, ex vivo methylation was shown to suppress the high basal activity of the ABO gene promoter.
Effect of DNA Demethylation on the ABO Gene ExpressionBased on the RT-PCR analysis, enzyme assays, and immunofluorostaining, we have shown that the absence of A-antigens in MKN28 cells seems to result from the down-regulation of the A-transferase mRNA transcript. Moreover, we have also shown that the ABO gene promoter region is hypermethylated in MKN28 cells. Therefore, the disappearance of A-antigens may be ascribed to hypermethylation of the ABO gene promoter in these cells. To address whether the methylation of the promoter region is itself inhibiting the expression of ABO genes, we treated MKN28 cells with 5-aza-2Ј-deoxycytidine, an agent that results in the demethylation of DNA, and then monitored the expression of the ABO transcripts by RT-PCR. Results are shown in Fig. 6A . A fragment of expected size was obtained by RT-PCR of RNA from MKN28 cells treated with 5 and 10 M concentrations of 5-aza-2Ј-deoxycytidine. This band was confirmed to be derived from A-transferase message by nucleotide sequencing and Southern blot hybridization using a radiolabeled A-transferase cDNA probe. MSP demonstrated that DNA from MKN28 cells treated with the reagent produced a PCR product with unmethylated primers, whereas the product was not detected before drug treatment. By sequence determination of the U products, some PCR products showed the conversion of all cytosine residues in CpG sites in the Ϫ192 to ϩ6 sequence of the ABO genes, whereas others indicated a large reduction in the number of methylated CpG sites per allele when compared with the results in Fig. 4A . These observations suggest that the reactivation of A gene is associated with the appearance of the demethylated ABO promoter in MKN28 cells after treatment. Although A-transferase activity was not significantly elevated in those MKN28 cells with the reagent, treatment with 5 and 10 M concentrations of 5-aza-2Ј-deoxycytidine has led to the appearance of A-antigen-positive cells at ratios of approximately 0.3 and 0.5%, respectively (Fig. 6B) . A-antigen-positive MKN28 cells were not observed in the control culture that did not contain 5-aza-2Ј-deoxycytidine. Therefore, it seems likely that DNA methylation is responsible for the absence of the ABO gene expression in MKN28 cells. After treatment, a small number of alleles with hypomethylation might have been involved in reactivation of A gene and may have led to the low frequencies of A-positive cells. Alternatively, an increase of a positive factor or a decrease of a negative factor may be required for effective expression of A gene in MKN28 cells in addition to DNA demethylation, because decreased methylation has been suggested to be a prerequisite for effective transcription following histone deacetylase inhibition (40) .
DISCUSSION
Our previous characterization of the ABO gene upstream region indicated that the sequence just upstream of the transcription start site was responsible for the transcriptional activity of the ABO genes (18) . The ABO gene promoter region is involved in a CpG island whose methylation status is known to be well correlated with gene expression. Bisulfite genomic sequencing and RT-PCR analysis show an inverse correlation of hypermethylation of the ABO gene promoter with the gene expression level. Although transient transfection experiments demonstrate constitutive transcriptional activity of the ABO gene promoter in both expressor (MKN45, KATOIII, and HEL) and nonexpressor (MKN28, Jurkat, and T98G) cell lines, this promoter activity is found diminished by a pretreatment of plasmid DNA before transfection with HhaI methylase, which catalyzed in vitro methylation of the HhaI CpG sites in the Ϫ117/Ϫ35 ABO promoter sequence. Confirmation of the importance of DNA methylation in ABO transcription is further demonstrated by treatment of gastric cancer cell line MKN28 cells with 5-aza-2Ј-deoxycytidine. Treatment resulted in demethylation of the ABO promoter region and expression of the ABO genes. These findings suggest that alterations in DNA methylation of the ABO promoter region may be one of the mechanisms regulating the human ABO gene expression. However, this does not exclude the possibility that a transcription factor essential for promoter activity or other negative regulatory factor(s), which could function outside of the ABO promoter, is involved in transcriptional regulation of the ABO genes.
Previously, the genomic DNA sequencing analysis using buffy coat DNA from healthy donors of blood group genotype A/A, B/B, O/O, and individuals of A 3 phenotype indicated neither nucleotide substitutions nor deletions in the ABO promoter sequence between Ϫ117 and ϩ31. 3 The genomic nucleotide sequences around the 5Ј upstream region of the ABO genes and a recent genetic population study (41) demonstrated that both B and O alleles are linked up with presence of four tandem copies of a 43-bp repeat unit located 3.8 kb upstream from the transcription start site and a 35-bp insertion located immediately 3Ј to the proximal Alu repeat. On the other hand, A 1 allele is linked up in the absence of the tandemly repetitive element and the 35-bp sequence. From those genetic investigations, at least the ABO promoter sequence is likely to be conserved among the ABO genes. Thus, the methylation status of the ABO promoter region could affect transcription of the human ABO genes.
The ability of methylation to silence genes with CpG islands appears largely to reflect on the conversion of the overall chromatin structure from an open to a closed configuration, whereas the unmethylated status is independent of whether a given gene is being actively transcribed (20) . Methylated sites on DNA bind the 5-methylcytosine-binding protein (MeCP2) which exists as a complex with Sin3A and histone deacetylase. This complex decreases the level of histone acetylation, resulting in a compact chromatin structure (42, 43) . Methylation of cytosine in the dinucleotide CpG has been suggested to be involved in the control of tissue-specific gene expression and has been shown to suppress transcription of a number of tissuespecific genes, such as myo-D (19), galectin-1 (31), embryonic globin (32) , and tissue transglutaminase gene (33) . The ABO genes are known to be expressed in a cell type-specific manner. To examine whether DNA methylation of CpG sites is involved in the control of tissue-specific expression of the ABO genes, various cell lines are investigated with regard to expression of the ABO genes and methylation status of the ABO promoter region. The nonexpressor cell lines, Jurkat and T98G, which were derived from T-lymphocytes and glial cells, show hypermethylation of the promoter region, whereas the expressor cell lines, MKN45, KATOIII, K562, and HEL, which were derived from either gastric cancer or erythroleukemia, show hypomethylation of the ABO gene promoter region. Thus, DNA methylation of the ABO promoter might be involved in the control of tissue-specific gene expression.
Neoplastic cells simultaneously harbor widespread genomic hypomethylation, more regional areas of hypermethylation, and increased DNA methyltransferase activity (20) . Each component of this "methylation imbalance" may fundamentally contribute to tumor progression. A main target of this regional hypermethylation is normally the CpG island located in the gene promoter region. This hypermethylation often correlates well with transcriptional repression that can serve as an alternative to mutations in the coding region for inactivation of tumor suppressor genes, including cyclin-dependent kinase inhibitor genes p16 and p15 (44 -47) , von Hippel-Lindau gene (48) , and E-cadherin gene (49) . The change of ABH antigen expression during carcinogenesis has been documented. Various human cancers often lose expression of histo-blood group A/B antigens, and this phenomenon has been correlated with the invasive and metastatic potentials of certain tumors and with mortality rates of the patients (13) (14) (15) (16) . Expression of H/Le y , the A/B precursors, was inversely correlated with the survival rate of the patients with lung carcinoma after surgery (14) . Disappearance of A/B antigens in human bladder tumors was initially ascribed to the absence of A/B-transferase gene expression rather than the loss of these genes in tumors (22) . However, the cases in which allelic loss seemed to be responsible for the loss of A/B antigens have recently been reported (50) . In the present study, most of the CpG sites in the ABO gene promoter are methylated in the human gastric cancer cell line MKN28 in which the ABO genes are silent. Treatment of these cells with 5-aza-2Ј-deoxycytidine results in demethylation of the ABO promoter region and appearance of the ABO gene messages. Thus, DNA methylation appears to be important in the reduction of the ABO gene expression in MKN28 cells. Considering that HhaI methylation of the plasmid DNA before DNA transfection results in a decrease, but not a complete loss of the promoter activity, other mechanism(s) may also exist that are responsible for the A/B antigen disappearance during tumorigenesis.
ABH antigens are known to undergo drastic changes during development, differentiation, and maturation. Studies of these antigens in stratified squamous epithelia provided one of the clearest examples of differential expressions during cell maturation (9) . In nonkeratinized stratified squamous epithelia, the immature cells in the basal layers are characterized by the expression of sialylated or unsubstituted precursor peripheral cores, whereas differentiated and mature cells in the upper layers sequentially express ␣132-fucosylated H structures and A and B antigens depending on the ABO genotype of the individual. This sequential expression of carbohydrate antigens is associated with the differentiation pattern of the epithelium. Keratinocytes are known to change greatly their gene expression during terminal cell differentiation. The expression of keratinocyte transglutaminase, which is an intracellular enzyme involved in cross-linking of intracellular proteins during terminal differentiation and cornification of skin cells, was shown to be regulated by DNA methylation (51) . Therefore, it is likely to assume that ABO gene expression is also influenced by methylation of the promoter region through cell differentiation.
Methylation of DNA has been proposed as a means of regulating gene expression although the role of DNA methylation in regulating tissue-specific gene expression is in light of the debate (52, 53) : the presence of tissue-specific methylation may be coincidental to or a result of gene silencing, rather than a controlling factor. However, the ABO gene expression in the cell type-specific manner, during tumorigenesis, and through cell differentiation can be plausibly explained by a single regulation, DNA methylation of the promoter region. An intriguing scenario has been proposed wherein multiple Sp1 sites located at both the 5Ј and 3Ј boundaries of the CpG island protect the island from the spread of methylation from the densely methylated flanking region often containing Alu repeat sequences (20, 28, 54, 55) . Because the genomic region 5Ј to the CpG island in the ABO genes also contains two Alu repeats, this model may fit well with the DNA methylation of the ABO genes if cell type-specific factors, in addition to a ubiquitous factor Sp1, are taken into consideration. Elucidation of such factors may lead to further and more precise resolution of a mechanism regulating DNA methylation and support the functional importance of DNA methylation.
